UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000013542
Receipt No. R000015774
Official scientific title of the study Does Quetiapine improve mood symptoms in schizophrenia patients?
Date of disclosure of the study information 2014/03/28
Last modified on 2016/06/19 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Does Quetiapine improve mood symptoms in schizophrenia patients?
Title of the study (Brief title) Does Quetiapine improve mood symptoms in schizophrenia patients?
Region
Japan

Condition
Condition Schizophrenia
Classification by specialty
Psychiatry
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the effectiveness of quetiapine on schizophrenia patients with depressive symptoms
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes HAM-D17
Key secondary outcomes BPRS
DIEPSS
Blood test

In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required.

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1.Chronic schizophrenia patients with depressive symptoms who have started the treatment with quetiapine
2.Patients whose positive symptoms are stable enough to keep a long term treatment with quetiapine
3.Patients who do not receive antidepressants
4.Age 18 and over
Key exclusion criteria Cases judged inadequate by medical doctor
Target sample size 30

Research contact person
Name of lead principal investigator Setsuko Yasugawa
Organization Yatsushiro Kosei Hospital
Division name Departmennt of psychiatry
Address Furushiromachi1705 Yatsushiro-shi Kumamoto
TEL 0965-33-4025
Email yasugawa@orange.ocn.ne.jp

Public contact
Name of contact person Setsuko Yasugawa
Organization Yatsushiro Kosei Hospital
Division name Departmennt of psychiatry
Address Furushiromachi1705 Yatsushiro-shi Kumamoto
TEL 0965-33-4025
Homepage URL
Email yasugawa@orange.ocn.ne.jp

Sponsor
Institute Yatsushiro Kosei Hospital
Institute
Department

Sponsor means an organization that is responsible for plan, deployment and
report of the research including funding management. It doesn't mean
funding agency". Therefore, all clinical trial should have the one.

Funding Source
Organization Astellas Pharma Inc.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 八代更生病院(熊本県)

Other administrative information
Date of disclosure of the study information
2014 Year 03 Month 28 Day

Progress
Recruitment status Completed
Date of protocol fixation
2014 Year 02 Month 01 Day
Anticipated trial start date
2014 Year 04 Month 01 Day
Last follow-up date
2016 Year 03 Month 31 Day
Date of closure to data entry
2016 Year 04 Month 01 Day
Date trial data considered complete
2016 Year 04 Month 01 Day
Date analysis concluded
2016 Year 06 Month 30 Day

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information Depressive symptoms in schizophrenia patients wil be described.

Management information
Registered date
2014 Year 03 Month 27 Day
Last modified on
2016 Year 06 Month 19 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015774